
Opinion|Videos|April 18, 2025
Identifying and Addressing Critical Gaps in Pediatric Atopic Dermatitis Treatment with Ruxolitinib Cream
Author(s)James Song, MD, FAAD
James Song, MD, FAAD, discusses how ruxolitinib cream addresses a significant treatment gap in pediatric atopic dermatitis by providing a non-steroidal topical option with efficacy comparable to medium-potency corticosteroids but without the associated safety concerns.
Advertisement
This news content has been independently developed and is not endorsed by the American Academy of Dermatology.
Video content above is prompted by the following:
- Where do you see the biggest gap in the current treatment paradigm for pediatric AD, and how might ruxolitinib cream help fill that gap?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Dermalogica Enters Medical Aesthetics with FDA-Cleared Microneedling PRO Pen
2
Social Media Mythbusters: Hypochlorous Acid Sprays
3
Quoin Submits First-Ever IND Application for Peeling Skin Syndrome Therapy
4
SkinJect Advances into Registrable Development as Potential First-in-Class Therapy for Gorlin Syndrome
5




















